Clopidogrel Resistance in Stroke Patients From Different Ethnicities

Ziv Hospital300 enrolled

Overview

Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Clopidogrel, Poor Metabolism of Ischemic Stroke

Interventions

Quantification of platelet aggregationDIAGNOSTIC_TEST

Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Ability to provide written informed consent and to be compliant with protocol assessments. 2. Ages 18 and above inclusive 3. Both genders eligible for the study 4. Diagnosis of ischemic cerebrovascular event Exclusion Criteria: 1. Pregnant patients will be excluded 2. Ages below 18 3. Patients not able to provide informed consent

Outcomes

Primary Outcomes

Rates of clopidogrel resistance assessed among the different ethnicities

Time frame: 6 months

Identifying of high-risk subgroups of adverse clinical outcomes

Time frame: 6 to 12 months